Compugen Ltd. (CGEN)
CGENNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$2.09
-0.0550 (-2.56%) today
At the close, Nov 10, 4:00 PM ET. After hours $2.09 –
- Market cap
- $197.68m
- P/E
- 5.4
- EPS, last 4 quarters
- $0.3900
- Dividend yield
- –
- Day range
- $2.03 to $2.14
- 52-week range
- $1.43 to $3.24
- Average volume
- 202.6k
- Previous close
- $2.15
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $4.50, +115.3% from here
Earnings
next estimate $-0.0500Next report
Dec 2025
+1100.0%
Mar 2026
-14.3%
Jun 2026
0.0%
Sep 2026
+25.0%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Compugen (CGEN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- What Compugen (CGEN) Said on Its Q3 Earnings CallMarketBeat · 1 day ago
- Compugen Ltd. Reports Third Quarter 2026 ResultsFintel · 1 day ago
- Compugen (CGEN) Reports Q3 Loss, Beats Revenue EstimatesZacks · 1 day ago
- Dentsply International (XRAY) Q3 Earnings and Revenues Miss EstimatesZacks · 5 days ago
- Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass EstimatesZacks · Nov 2, 2026
- Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor TargetsMarketBeat · Oct 5, 2026
The company
Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- cgen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.